Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) has highlighted the publication of a peer-reviewed randomized clinical trial in the Journal of American Medical Association (JAMA) Network Open evaluating a single dose of psilocybin in adults with cocaine use disorder.
According to Red Light, following its acquisition of Filament Health, the company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament’s patented botanical drug candidate, PEX010. PEX010, has received Phase 2 clinical trial authorization in stimulant use disorder from both the FDA and Health Canada.
In a statement, Todd Shapiro, CEO and director of Red Light, commented, “This is exactly the kind of science we set out to be associated with when we acquired Filament. Dr. Hendricks lead investigator and professor in the department of psychiatry and behavioral neurobiology at the University of Alabama at Birmingham and his team have produced the first randomized data showing that a single dose of psilocybin can help people with cocaine use disorder, a population that has been waiting decades for a treatment that works, and one that has been largely overlooked by the rest of the field.”
He added, “We are proud that Filament holds the exclusive worldwide license to this dataset, and we believe it provides a strong foundation for advancing PEX010, our patented natural psilocybin drug candidate, through Filament’s authorized Phase 2 program in stimulant use disorder. There is real work ahead, and these results need to be replicated in larger trials, but today is a meaningful day for patients, for science, and for our company.”
